Last reviewed · How we verify
NCT01851382
Collection of Saliva and/ or Peripheral Blood From Healthy Volunteers for Research
trial in Graft vs Host Disease in 29 participants. Completed in 12 February 2015.
10 July 2014
Quick facts
| Lead sponsor | National Cancer Institute (NCI) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 29 |
| Start date | 15 May 2013 |
| Primary completion | 10 July 2014 |
| Estimated completion | 12 February 2015 |
| Sites | 1 location across United States |
Conditions studied
- Graft vs Host Disease — all drugs for Graft vs Host Disease →
- Healthy Volunteer — all drugs for Healthy Volunteer →
- Graft-Versus-Host Disease — all drugs for Graft-Versus-Host Disease →
Sponsor
National Cancer Institute (NCI)
Who can join
Adults 18 to 99, any sex, with Graft vs Host Disease or Healthy Volunteer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: \- Researchers often collect samples from healthy volunteers to further their research. These samples can help better understand serious side effects and complications of transplant treatments in patients. This study will collect saliva samples from healthy volunteers. Objectives: \- To collect saliva and blood samples from healthy volunteers for research studies. Eligibility: \- Healthy men ages 30-70 years for Phase I of the study. Design: * Participants will be screened with a medical history questionnaire. They will also have a brief oral exam to check for any mouth infection. * Participants will provide a saliva sample. The collection process will take about 5 minutes. * No treatment will be given as part of this study.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Salivary ZG16B expression loss follows exocrine gland dysfunction related to oral chronic graft-versus-host disease.
Costa-da-Silva AC, Aure MH, Dodge J, Martin D, et al · · 2022 · cited 30× · PMID 35005541 · DOI 10.1016/j.isci.2021.103592
Verify or expand the search:
- PubMed search for NCT01851382
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Graft vs Host Disease
Currently open trials in the same condition.
- NCT07184853 — Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD · NA · recruiting
- NCT06568328 — Chimeric Natural Killer Receptor-Universal T Cells for Refractory GVHD · Phase 1 · recruiting
- NCT05531786 — Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) Af · Phase 1, PHASE2 · recruiting
- NCT04044365 — Pediatric cGVHD Symptom Scale · recruiting
- NCT02105766 — Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Bet · Phase 2 · active not recruiting
Other National Cancer Institute (NCI) trials
Trials by the same sponsor.
- NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
- NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
- NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01851382 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
- Last refreshed: 11 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01851382.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing